Hutchinson Technology CEO Discusses F4Q2010 Results - Earnings Call Transcript

Hutchinson Technology, Inc. (HTCH)

F4Q2010 Earnings Call Transcript

November 1, 2010 5:00 pm ET

Executives

Chuck Ives – IR Manager

Wayne Fortun – President & CEO

Kathleen Skarvan – VP & President of Disk Drive Components Division

Rick Penn – SVP & President of BioMeasurement Division

Dave Radloff – VP & CFO

Analysts

Kevin McFesson [ph] – Deutsche Bank

Matt Swope – Gleacher Securities

Rich Kugele – Needham & Company

Tom Lewis – High Road Value Research

Mark Miller – Noble Financial

Aaron Rakers – Stifel Nicolaus

Eric Rubel – MTR Securities

Presentation

Operator

Compare to:
Previous Statements by HTCH
» Hutchinson Technology Incorporated F3Q10 (Qtr End 06/27/10) Earnings Call Transcript
» Hutchinson Technology Inc. F2Q10 (Qtr End 03/28/10) Earnings Call
» Hutchinson Technology F1Q10 (Qtr End 12/27/09) Earnings Call Transcript
» Hutchinson Technology Inc. F4Q09 (Qtr End 27/09/09) Earnings Call Transcript

Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Hutchinson Technology fourth quarter results conference call. During today’s presentation all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. (Operator instructions)

This conference is being recorded today, Monday, November 1, 2010. I would now like to turn the conference over to Chuck Ives, Treasurer and Director of Investor Relations. Please go ahead, sir.

Chuck Ives

Good afternoon, everyone. Welcome to our fourth quarter results conference call. On the call with me today are Wayne Fortun, our Chief Executive Officer; Kathleen Skarvan, President of our Disk Drive Components Division; Rick Penn, President of our BioMeasurement Division; and Dave Radloff, our Chief Financial Officer.

As a reminder, we will be providing forward-looking information on demand for and shipments of the company’s products, production capabilities and capacity, capital spending, pricing, product costs, cost reductions, operating expenses, our assembly operation in Thailand, our BioMeasurement Division’s revenue, product commercialization and adoption, and the company’s operating performance and financial results.